RxDoctor Payments Data

Michael Zager, MD

Internal Medicine · Allentown, PANPI 1326087362

Payments from drug & device makers

$1,464in general payments, 2019–2025

Across 96 payments — averaging $15.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$734
  • AstraZeneca$162
  • Amgen$126
  • Lilly USA, LLC$97
  • AbbVie$88
  • Boehringer Ingelheim$74
  • plus $184 from 8 others

What the payments were for

  • Food & beverage$1,464100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,464 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$173,958
Medicare patients
628
Services billed
2,047

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Metformin Er GastricMetformin Hcl15$81,146
EliquisApixaban75$69,462
OzempicSemaglutide59$67,260
JardianceEmpagliflozin66$64,651
MyrbetriqMirabegron54$50,353
JanuviaSitagliptin Phosphate38$44,726
RybelsusSemaglutide21$33,832
LinzessLinaclotide30$24,240
XareltoRivaroxaban28$22,528
InvokanaCanagliflozin11$16,224
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$16,175
RestasisCyclosporine18$12,722
EntrestoSacubitril/Valsartan11$12,587
Breo ElliptaFluticasone/Vilanterol16$11,480
Tresiba Flextouch U-100Insulin Degludec20$9,876

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$734$101,09280 claims
PfizerEliquis$17$69,46275 claims
Boehringer IngelheimJardiance$74$64,65166 claims
MerckJanuvia, Janumet Xr$17$51,04249 claims
AbbVieLinzess, Restasis, Synthroid$88$40,307107 claims
Johnson & JohnsonXarelto, Invokana$56$38,75239 claims
GSKTrelegy Ellipta, Breo Ellipta$14$27,65535 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →